Skip to main content

Table 1 Clinicopathologic characteristics and overall survival information of 444 patients with gastric cancer who underwent gastrectomy

From: Prognostic value of systemic immune-inflammation index in patients with gastric cancer

Characteristic

No. of patients (%)

Mean OS with 95% CI (months)

P valueb

Sex

  

0.170

 Man

281 (63.3)

54 (48–60)

 

 Woman

163 (36.7)

61 (53–69)

 

Age (years)

  

0.061

 <60

249 (56.1)

60 (53–66)

 

 ≥60

195 (43.9)

53 (46–59)

 

Tumor location

  

0.043

 Upper stomach

140 (31.5)

48 (40–56)

 

 Middle stomach

137 (30.9)

58 (50–67)

 

 Lower stomach

167 (37.6)

62 (54–70)

 

Tumor size (cm)

  

<0.001

 <5

221 (49.8)

73 (66–80)

 

 ≥5

223 (50.2)

40 (34–46)

 

Pathologic type

  

0.330

 Adenocarcinoma

367 (82.7)

57 (52–62)

 

 Squamous carcinoma

25 (5.6)

50 (28–71)

 

 Adenosquamous carcinoma

3 (0.7)

37 (18–57)

 

 Ring cell carcinoma

39 (8.8)

53 (36–69)

 

 Undifferentiated carcinoma

10 (2.3)

86 (39–133)

 

Borrmann classification

  

<0.001

 1

30 (6.8)

78 (55–102)

 

 2

98 (22.1)

76 (66–85)

 

 3

259 (58.3)

55 (49–61)

 

 4

50 (11.3)

20 (12–29)

 

 5

7 (1.6)

30 (3–55)

 

pTa

  

<0.001

 1

53 (11.9)

99 (87–110)

 

 2

41 (9.2)

89 (76–103)

 

 3

175 (39.4)

59 (52–65)

 

 4

175 (39.4)

34 (27–41)

 

pNa

  

<0.001

 0

152 (34.2)

92 (85–100)

 

 1

185 (41.7)

42 (36–48)

 

 2

77 (17.3)

34 (25–43)

 

 3

30 (6.8)

24 (12–37)

 

pMa

  

<0.001

 0

337 (75.9)

67 (63–73)

 

 1

107 (24.1)

21 (14–27)

 

TNM stagea

  

<0.001

 I

77 (17.3)

101 (92–110)

 

 II

64 (14.4)

79 (67–90)

 

 III

196 (44.1)

52 (45–58)

 

 IV

107 (24.1)

21 (14–27)

 

CEA (μg/L)

  

0.023

 <5

399 (89.9)

59 (54–63)

 

 ≥5

45 (10.1)

39 (26–53)

 

NLR

  

0.510

 <2.10

205 (46.2)

65 (58–72)

 

 ≥2.10

239 (53.8)

49 (43–56)

 

PLR

  

0.201

 <120

144 (32.4)

67 (59–76)

 

 ≥120

300 (67.6)

51 (46–57)

 

SII

  

<0.001

 <660

283 (63.7)

65 (59–71)

 

 ≥660

161 (36.3)

42 (35–49)

 
  1. OS, overall survival; CI, confidence interval; CEA, carcinoembryonic antigen; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; SII, systemic immune-inflammation index
  2. aTumor stage was defined according to the 2010 American Joint Committee on Cancer (AJCC) TNM staging system
  3. bANOVA analysis was used to compare the OS